NCT07197320

Brief Summary

Chemotherapy is an essential component of breast cancer treatment. Frequent intravenous injections may lead to phlebitis and limited venous access, therefore implantable venous ports are increasingly used. The choice of port placement side in breast cancer patients is controversial, especially when mastectomy or radiotherapy is planned. This retrospective cohort study compares one-year patency, complications (infection, thrombosis, skin necrosis), and functional outcomes of ports implanted via the right internal jugular vein in patients with right versus left breast cancer.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
80

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Nov 2025

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 21, 2025

Completed
8 days until next milestone

First Posted

Study publicly available on registry

September 29, 2025

Completed
1 month until next milestone

Study Start

First participant enrolled

November 1, 2025

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2026

Completed
28 days until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2026

Completed
Last Updated

September 29, 2025

Status Verified

September 1, 2025

Enrollment Period

3 months

First QC Date

September 21, 2025

Last Update Submit

September 21, 2025

Conditions

Port-A-Cath

Keywords

chemotherapyportmastectomybreast cancerOne-year patency

Outcome Measures

Primary Outcomes (1)

  • . One-year port patency

    Defined as functional port access without removal due to complications

    12 months after port implantation

Secondary Outcomes (4)

  • Infection

    12 months

  • Thrombosis

    12 months

  • skin necrosis

    12 months

  • cancer side association

    12 months

Study Arms (2)

Cohort 1

Patients with right-sided breast cancer who received a right internal jugular port

Cohort 2

Patients with left-sided breast cancer who received a right internal jugular port

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

All breast cancer patients receiving right internal jugular venous port implantation in Gorgan medical centers (2017-2024).

You may qualify if:

  • Female patients with breast cancer (right or left side)
  • Underwent chemotherapy port implantation via right internal jugular vein between 2017-2024 in Gorgan medical centers

You may not qualify if:

  • Prior neck surgery or radiotherapy involving right jugular area
  • Incomplete medical records

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

5Th Azar Medical Center

Gorgan, Outside of the US, 4917956808, Iran

Location

MeSH Terms

Conditions

Breast Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsBreast DiseasesSkin DiseasesSkin and Connective Tissue Diseases

Central Study Contacts

Pezhman Kharazm

CONTACT

+989111751861pezhmankh@goums.ac.ir

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor of Vascular Surgery

Study Record Dates

First Submitted

September 21, 2025

First Posted

September 29, 2025

Study Start

November 1, 2025

Primary Completion

February 1, 2026

Study Completion

March 1, 2026

Last Updated

September 29, 2025

Record last verified: 2025-09

Locations

IR(1)